Epidemiologists question genotyping value with Plavix therapy
This article was originally published in Scrip
Executive Summary
Epidemiologists at University College London and the London School of Hygiene and Tropical Medicine, have through the publication of a meta-analysis in the Journal of the American Medical Association, triggered a row between Professors Steven Nissen and Eric Topol over the usefulness of cytochrome P450 subclass 2C19 (CYP2C19) genotyping as a predictor of response to Plavix clopidogrel therapy.